SYNALAR OINTMENT

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

FLUOCINOLONE ACETONIDE

から入手可能:

BAUSCH HEALTH, CANADA INC.

ATCコード:

D07AC04

INN（国際名）:

FLUOCINOLONE ACETONIDE

投薬量:

0.025%

医薬品形態:

OINTMENT

構図:

FLUOCINOLONE ACETONIDE 0.025%

投与経路:

TOPICAL

パッケージ内のユニット:

60G

処方タイプ:

Prescription

治療領域:

ANTI-INFLAMMATORY AGENTS

製品概要:

Active ingredient group (AIG) number: 0106314001; AHFS:

認証ステータス:

APPROVED

承認日:

1998-09-02

製品の特徴

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
SYNALAR
®
Fluocinolone Acetonide
Ointment 0.025% w/w
TOPICAL CORTICOSTEROID
BAUSCH HEALTH, CANADA INC.
Date of Initial Approval:
2150 St-Elzear Blvd. West
November 17, 2014
Laval, Quebec
H7L 4A8
DATE OF REVISION:
June 25, 2021
Control #: 247002
_Pr_
_SYNALAR _
_®_
_ Page 2 of 13 _
_(Fluocinolone Acetonide) _
RECENT MAJOR LABEL CHANGES
Not applicable
TABLE OF CONTENTS
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................3
1
INDICATIONS
...........................................................................................................3
1.1
Pediatrics……………………………………………………………………………....3
1.2
Geriatrics……………………………………………………………………………....3
2
CONTRAINDICATIONS
...........................................................................................3
3
DOSAGE AND
ADMINISTRATION.........................................................................3
3.1 Dosing Considerations
…………………………………….…………………………..3
3.2 Recommended Dose and Dosage Adjustment
....................................................... ..3
3.3Administration…………………………………………………………………………3
4
OVERDOSAGE
..........................................................................................................4
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ...............4
6
WARNINGS AND PRECAUTIONS
..........................................................................4
7
ADVERSE REACTIONS
...........................................................................................5
8
DRUG
INTERACTIONS………………………………………………………………..5
9 CLINICAL PHARMACOLOGY
..............................................................................5
9.1
Pharmacokinetics.............